Malin Hultqvist is the CEO of Redoxis and holds a PhD in Medical Inflammation Research from Lund University, with deep scientific expertise in immune regulation and preclinical disease models. She joined Redoxis in 2008 and has since been instrumental in shaping the company’s scientific direction and growth.
Throughout her tenure, Malin has held key leadership positions, including CSO and Director of CRO Services, before assuming the CEO role in 2016. Under her leadership, Redoxis has significantly expanded its laboratory capabilities, strengthened its scientific portfolio across in vivo, in vitro, and advanced analytical services, and grown a diverse international client base.
Malin is dedicated to connecting academic innovation with robust and reliable contract research, ensuring that Redoxis remains a trusted partner in early drug development. She leads with a strong focus on scientific excellence, customer collaboration, and building a sustainable, supportive environment for the team.
